<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20240510061726N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-07-29</date_registration>
      <primary_sponsor>Khoy University of medical science</primary_sponsor>
      <public_title>The effect of oral tablet of Black cohosh on the menstrual symptoms and dysmenorrhea</public_title>
      <acronym></acronym>
      <scientific_title>The effect of oral tablet of Black cohosh on the menstrual symptoms and dysmenorrhea among female students: a randomized controlled trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-05-14</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/76769</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Other, Purpose: Treatment, Randomization description: The list of students is taken and they are selected by a simple random method and they are contacted. Qualified people are randomly allocated into two black cohosh groups using a random block size of four and six blocks and with a ratio of 1:1. and a placebo will be placed. The pills are placed in opaque bottles numbered consecutively and will be delivered to the participants in the order they enter the study. The researcher and the participants will not know the type of drug. It should be noted that the placebo will be completely similar to the original drug in terms of shape, color, and other appearance characteristics and will be manufactured by the pharmaceutical company, Blinding description: In this study, there will be three blinded sides.Participants, the researcher and the analyst will be blind. The type of original drug and placebo will be the same in terms of shape, color, smell and size, and none of the participants will be aware of the type of drug used. In the same way, the researcher and the analyst will not know the type of drug and the list of drugs will be at the disposal of the person not involved in the study.</study_design>
      <phase>3</phase>
      <hc_freetext>Dysmenorrhea and premenstrual symptoms.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: For the intervention group, black cohosh herbal medicine with the medicinal name of Simi Fogel, which Gol Daru Company manufactures, will be used. This medicine is in the form of coated tablets that contain 6.5 mg of dry extract of black cohosh root. This medicine will be taken 7 tablets monthly (5 tablets on the day before menstruation and 2 tablets during menstruation) by female students for 2 months. The pharmacist approves this treatment protocol of the team, and in previous similar articles, the same dose has been used on menopause. Intervention 2: Control group: For the control group, the placebo drug will be made exactly the same as the original drug by Isfahan Gol Daru Company.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Parts of the data, such as information related to the main outcome, will be report after de-identifying people

When:
The access period starts 6 months after the results are published

To whom:
researchers and students

Conditions:
Study data can only be used by mentioning the source

Where to obtain:
The scientific response of the study to the treatment of Nasrin Zamiri Miandoab with the email address nasriinzamiri@gmail.com

How to obtain:
The applicant can receive the data by sending an email to the corresponding author

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>nasrin zamiri-miandoab</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>khoy, Valiasr blvd,</address>
        <city>khoy</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5816753464</zip>
        <telephone>+98 44 3625 5777</telephone>
        <email>nasriinzamiri@gmail.com</email>
        <affiliation>khoy university of medical science</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Nasrin zamiri-miandoab</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Khoy, Valiasr Blvd</address>
        <city>Khoy</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5816753464</zip>
        <telephone>0098443625777</telephone>
        <email>nasriinzamiri@gmail.com</email>
        <affiliation>Khoy University of medical science</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Regular menstruation 21-35 days
Age 18-30 years
insensitivity to black cohosh and other herbal medicines containing phytoestrogens (soybeans, flax seeds, lentils, mung beans, etc.) According to the person's statement
Not taking any medication to treat dysmenorrhea at the same time as research
Having primary dysmenorrhea (with VAS score ≥ 4)
Not having liver problems according to the person's own statement
not married
Complaining of menstrual symptoms (cramps, headache, abdominal pain, mood disorders, etc.)</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>30 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>First semester students
Use of other herbal medicines and painkillers.
The occurrence of a stressful event (such as the death of a first-degree family member and the diagnosis of an incurable or incurable disease for a family member during the last three months)
Abuse of tobacco and alcohol
Having any acute or chronic disease (such as epilepsy, cardiovascular, digestive, liver, blood, endocrine)
History of any female disease such as abnormal pelvic anatomy, lack of ovulation, or abnormal pattern of uterine bleeding
Surgery in the last three months
Insensitivity to black cohosh and other herbal medicines containing phytoestrogens (soybeans, flax seeds, lentils, mung beans, etc.)according to the person's statement.
Taking antidepressants (such as serotonin and noradrenaline reuptake inhibitors, antihistamines, barbiturates, narcotics, diazepam, amphetamines, and cocaine)</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N94.4</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Primary dysmenorrhea</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: For the intervention group, black cohosh herbal medicine with the medicinal name of Simi Fogel, which Gol Daru Company manufactures, will be used. This medicine is in the form of coated tablets that contain 6.5 mg of dry extract of black cohosh root. This medicine will be taken 7 tablets monthly (5 tablets on the day before menstruation and 2 tablets during menstruation) by female students for 2 months. The pharmacist approves this treatment protocol of the team, and in previous similar articles, the same dose has been used on menopause</i_keyword>
      <i_keyword>Control group: For the control group, the placebo drug will be made exactly the same as the original drug by Isfahan Gol Daru Company</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Menstrual symptoms. Timepoint: The beginning of the study and the end of the study. Method of measurement: Menstrual symptoms intensity scale SSS.</prim_outcome>
      <prim_outcome>Primary dysmenorrhea. Timepoint: The beginning of the study and the end of the study. Method of measurement: visual pain scale (VAS).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Khoy University of medical science</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-05-01</approval_date>
        <contact_name>Ethics committee of khoy  University of Medical Sciences</contact_name>
        <contact_address>khoy, Valiasr Blvd, khoy  University of Medical Sciences خوی West Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
